

FIG.1 REACTIVITY OF ANTI-FACTOR D MABs WITH FACTOR D IN ELISA




FIG.2

INHIBITION OF AP HEMOLYSIS BY ANTI-FACTOR D ANTIBODY 166-32




FIG. 3

INHIBITION OF ALTERNATIVE PATHWAY HEMOLYSIS  
BY MAb 166-32 IN 90% HUMAN SERUM




Figure 4 shows the effect of anti-factor D mAb 166-32 on CP hemolysis. The graph shows that the mAb 166-32 inhibits CP hemolysis in a dose-dependent manner. The mAb 166-32 is the most effective, followed by mAb 137-76 and mAb G3-519.

FIG. 4

EFFECT OF ANTI-FACTOR D MAb 166-32 ON CP HEMOLYSIS




FIG.5 INHIBITION OF FACTOR D DEPENDENT AP HEMOLYSIS BY MAb 166-32




FIG.6

EFFECT OF ANTI-FACTOR D MAb 166-32 ON  
FACTOR D DEPENDENT EAC3b CELL LYSIS




FIG.7

EFFECT OF MAb 166-32 ON C3 $\alpha$  PRODUCTION  
VIA AP COMPLEMENT ACTIVATION ON ZYMOSAN




FIG. 8

EFFECT OF MAb 166-32 ON SC5b-9 PRODUCTION  
VIA AP COMPLEMENT ACTIVATION ON ZYMOSAN








FIG.9

INHIBITION OF AP HEMOLYSIS BY ANTI-FACTOR D  
ANTIBODY 166-32 AND ITS Fab FRAGMENT



Year	1970	1971	1972	1973	1974	1975	1976	1977	1978	1979	1980	1981	1982	1983	1984	1985	1986	1987	1988	1989	1990	1991	1992	1993	1994	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026	2027	2028	2029	2030	2031	2032	2033	2034	2035	2036	2037	2038	2039	2040	2041	2042	2043	2044	2045	2046	2047	2048	2049	2050	2051	2052	2053	2054	2055	2056	2057	2058	2059	2060	2061	2062	2063	2064	2065	2066	2067	2068	2069	2070	2071	2072	2073	2074	2075	2076	2077	2078	2079	2080	2081	2082	2083	2084	2085	2086	2087	2088	2089	2090	2091	2092	2093	2094	2095	2096	2097	2098	2099	2100
1970	1971	1972	1973	1974	1975	1976	1977	1978	1979	1980	1981	1982	1983	1984	1985	1986	1987	1988	1989	1990	1991	1992	1993	1994	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026	2027	2028	2029	2030	2031	2032	2033	2034	2035	2036	2037	2038	2039	2040	2041	2042	2043	2044	2045	2046	2047	2048	2049	2050	2051	2052	2053	2054	2055	2056	2057	2058	2059	2060	2061	2062	2063	2064	2065	2066	2067	2068	2069	2070	2071	2072	2073	2074	2075	2076	2077	2078	2079	2080	2081	2082	2083	2084	2085	2086	2087	2088	2089	2090	2091	2092	2093	2094	2095	2096	2097	2098	2099	2100	

FIG. 10



EPITOPE MAPPING OF MAb 166-32 USING BACULOVIRUS-EXPRESSED FACTOR D MUTANTS




FIG. 12

SCHEMATIC REPRESENTATION OF THE EXPRESSION VECTOR PLASMIDS FOR  
CHIMERIC 166-32 Fab: (A) pSV2dhfrFd AND (B) pSV2neoK





FIG.13

INHIBITION OF AP HEMOLYSIS BY ANTI-FACTOR D  
ANTIBODY 166-32 AND ITS CHIMERIC FORM



**FIG.14** INHIBITION OF AP HEMOLYSIS BY CHIMERIC 166-32 IgG AND ITS Fab




FIG. 15


EFFECTS OF MAb 166-32 ON LVEDP AND LVDP  
OF ISOLATED RABBIT HEARTS PERFUSED WITH HUMAN PLASMA

FIG. 16

EFFECT OF 4% HUMAN PLASMA ON VENTRICULAR  
CONTRACTILE FUNCTION : RABBIT ISOLATED HEART






FIG. 17

EFFECTS OF MAb 166-32 ON THE LEVELS OF  
Bb IN CARDIAC LYMPH OF ISOLATED  
RABBIT HEARTS PERFUSED WITH HUMAN PLASMA




FIG. 18

ALTERNATIVE PATHWAY HEMOLYTIC ACTIVITY OF  
PLASMA FROM EXTRACORPOREAL CIRCUITS




FIG. 19 C3a PRODUCTION IN EXTRACORPOREAL CIRCUITS




FIG. 20

sC5b-9 PRODUCTION IN EXTRACORPOREAL CIRCUITS




FIG.21

Bb PRODUCTION IN EXTRACORPOREAL CIRCUITS




FIG. 22 C4d PRODUCTION IN EXTRACORPOREAL CIRCUITS





Figure 23 shows the effect of time on the expression of CD11b on neutrophils in extracorporeal circuits. The data is presented in the following table:

FIG. 23

CD11b EXPRESSION ON NEUTROPHILS IN EXTRACORPOREAL CIRCUITS



After 10 min, the cells were washed with PBS and then stained with anti-CD62P antibody. The cells were then analyzed by flow cytometry.

FIG. 24






FIG.25





Fig. 26 Selective inhibition of the alternative complement pathway  
by anti-factor D MAb 166-32



Bb concentration ( $\mu\text{g/ml}$ )




Fig. 27 Bb production in extracorporeal circuits

Fig. 28 C4d production in extracorporeal circuits




Fig. 29 C3a production in extracorporeal circuits




Fig. 30 sC5b-9 production in extracorporeal circuits




Fig. 31 C5a production in extracorporeal circuits




Fig. 32 CD11b expression on neutrophils in extracorporeal circuits






Fig. 33 Myeloperoxidase production in extracorporeal circuits




Fig. 34 Elastase-α1-antitrypsin production in extracorporeal circuits

Fig. 34 Elastase-α1-antitrypsin production in extracorporeal circuits




Fig. 35 CD62P expression on platelets in extracorporeal circuits




Fig. 36 CD62P-positive platelets in extracorporeal circuits




Fig. 37 Platelet thrombospondin production in extracorporeal circuits






Fig. 38 IL-8 production in extracorporeal circuits




**Fig. 39 Pharmacokinetics of MAb166-32 in Baboon CPB**

(5 mg/kg MAb166-32, single iv. bolus)




**Fig. 40 Inhibition of Alternative Complement  
by MAb166-32 in Baboon CPB**







# Fig. 41 Bb in Baboon CPB




**Fig. 42 C4d in Baboon CPB**




**Fig. 43 C3a in Baboon CPB**







**Fig.45 CD11b Expression on Monocytes in Baboon CPB**




**Fig. 4b CD62P Expression on Platelets in Baboon CPB**



**Fig. 47 Plasma IL-6 in Baboon CPB**




**Fig. 48 Plasma LDH Level in Baboon CPB**






**Fig. 49 Plasma Creatine Kinase (CK) Level in Baboon CPB**




**Fig. 50 Plasma Creatine Kinase Isozymes (CK-MB) in Baboon CPB**



**Fig. 51 Plasma Creatinine Level in Baboon CPB**

(18 hr post-CPB,  $p=0.01$ )



**Fig. 52 Dynamic Lung Compliance of Baboons in CPB**

